FDA Clearance Tracker · P100020-S004
ROCHE COBAS HPV TEST
Last checked: Nov 20, 2026Latest source record: Jun 25, 2013 (this decision)Source: openFDAMethods & limitations
Decided
Jun 25, 2013
Approved
Time to decision
449 days
Received Apr 2, 2012. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P100020-S004
- Device name
- ROCHE COBAS HPV TEST
- Applicant
- Roche Molecular Systems, Inc.
- Applicant location
- Pleasanton, CA
- Received
- Apr 2, 2012
- Decided
- Jun 25, 2013
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P100020
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR PROCESSING OF RESIDUAL CERVICAL SAMPLE DIRECTLY FROM THE PRESERVCYT¿ VIAL (HOLOGIC, INC., BEDFORD, MA) AFTER PROCESSING FOR LIQUID-BASED CYTOLOGY (LBC) USING EITHER THE HOLOGIC THINPREP® 2000 OR THINPREP® 3000 PROCESSORS AND TESTING ON THE COBAS® 4800 SYSTEM DIRECTLY FROM THE PRESERVCYT VIAL (PRIMARY VIAL). APPROVAL FOR CAPABILITY TOADD OPTIONAL NON-IVD SOFTWARE TO THE COBAS® 4800 SYSTEM THAT IS USED TO PERFORM THE COBAS® HPV TEST WAS ALSO REQUESTED.
Source documents
Other decisions for Roche Molecular Systems, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260045 · Decided Aug 28, 2026 · 233 days after receipt
Device type: C. Difficile Toxin Gene Amplification Assay (OZN) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.